Search research articles
Contact Us
Filters
Showing results (51-60 of 72) with videos related to
Page
of 8
Sort By:
Revue Des Maladies Respiratoires
|
February 22, 2008
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]
D Moro-Sibilot, F Barlesi, J F Timsit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2003
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer
E Quoix, B Lebeau, A Depierre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors
F Barlési, C Balleyguier, B Besse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2015
High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets
V Fallet, R Saffroy, N Girard, et al.
Respiratory Medicine and Research
|
June 22, 2020
Proposals for managing patients with thoracic malignancies during COVID-19 pandemic
N Girard, L Greillier, G Zalcman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 3, 2005
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin
J-L Pujol, J-L Breton, R Gervais, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
J Mazières, F Barlesi, T Filleron, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 19, 2018
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
J von Pawel, R Bordoni, M Satouchi, et al.
ESMO Open
|
December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O Molinier, B Besse, F Barlesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
C Leduc, J P Merlio, B Besse, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 72) with videos related to
Sort By:
Page
of 8
Revue Des Maladies Respiratoires
|
February 22, 2008
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]
D Moro-Sibilot, F Barlesi, J F Timsit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2003
Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer
E Quoix, B Lebeau, A Depierre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors
F Barlési, C Balleyguier, B Besse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2015
High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets
V Fallet, R Saffroy, N Girard, et al.
Respiratory Medicine and Research
|
June 22, 2020
Proposals for managing patients with thoracic malignancies during COVID-19 pandemic
N Girard, L Greillier, G Zalcman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 3, 2005
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin
J-L Pujol, J-L Breton, R Gervais, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
J Mazières, F Barlesi, T Filleron, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 19, 2018
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
J von Pawel, R Bordoni, M Satouchi, et al.
ESMO Open
|
December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O Molinier, B Besse, F Barlesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
C Leduc, J P Merlio, B Besse, et al.
Page
of 8